September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Efficacy of Intravitreal Bevacizumab injection for the treatment of
Vitreous hemorrhage
Author Affiliations & Notes
  • Jungyong Kim
    Department of Ophthalmology, Inha university hospital, Incheon, Korea (the Republic of)
  • Hee Seung Chin
    Department of Ophthalmology, Inha university hospital, Incheon, Korea (the Republic of)
  • Footnotes
    Commercial Relationships   Jungyong Kim, None; Hee Seung Chin, None
  • Footnotes
    Support  Nobe
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 6333. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Jungyong Kim, Hee Seung Chin; Efficacy of Intravitreal Bevacizumab injection for the treatment of
      Vitreous hemorrhage. Invest. Ophthalmol. Vis. Sci. 2016;57(12):6333.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate the efficacy of intravitreal Bevacizumab injection for the treatment of vitreous hemorrhage patients with retinal vascualr disease.

Methods : 139 Eyes of 126 patients of vitreous hemorrhage treated with Bevacizumab of 1.25~2.50mg(0.05~0.1ml) from 2007 to 2015 were retrospectively reviewed. Best-corrected visual acuity(BCVA) for before injection, one and three months after injections, were recored. All the patinets have been observed over three months. Clearing of vitreous hemorrhage was reviewed with Fundus record and fundus photography.

Results : 139 eyes of 126 patients were considered. Two main causes of vitreous hemorrhage were proliferative diabetic retinopathy (105 patients,75%) and BRVO (17 patients,12%). Mean one month (logMAR;0.69) and three month (logMAR;0.62) after injection visual acuity was better than baseline visual acuity (logMAR;1.23). Even intravitreal injection for controlling vitreous hemorrhage, vitrectomy was performed for 51 patients(40%). Average clearing time of vitreous hemorrhage was 40.7 days. Intravitreal Bevacizumab injection for previous PRP group (logMAR;0.79) showed better outcome of visual acuity improvement compared to Bevacizumab injection after PRP group (logMAR 0.09). Previous PRP group performed less average injection (1.75) for controlling vitreous hemorrhage compared to after PRP group (2.73).

Conclusions : Intravitreal Bevacizumab injection is especially efficient for the treatment of new vitreous hemorrhage for patient with PDR to improve visual acuity after injection. It reduces the hemorrhage and facilitates vitrectomy. Our study shows that intravitreal Bevacizumab injection for prior complete PRP group has shown improved visual acuity and less injection performed for regression of vitreous hemorrhage compare to injection after PRP group. Therefore, intravitreal Bevacizumab injection can be an initial option for treatment of vitreous hemorrhage patients with retinal vascular disease.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×